A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Alcaftadine; Dextrans; Lubricant Eye Drops; Olopatadine Hydrochloride; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• History of eye allergies within the past 24 months

• Willing to not wear contact lenses at least 72 hours prior to the study start and during the study period

Exclusion Criteria:

• Current eye infection

• Eye surgery within 3 months or vision correction surgery within 6 months

• Any planned surgery during the study or 30 days after the study